MYGN insider buying and SEC filings, explained

Myriad Genetics Inc. · CIK 899923

Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov

Insider activity in the last 12 months

Bought

$722K

Insiders who bought

Sold (not marked 10b5-1)

Planned sales (10b5-1)

$67K

Traded	Type	What was filed	Source
Jun 8, 2026	Planned (10b5-1)	Rashmi Kumar (Director) sold 15,000 shares at about $4.46 ($67K), marked as a 10b5-1 plan trade. Holdings down 8% to 171,889 shares.	SEC filing Filed Jun 9, 2026
May 14, 2026	Purchase (code P)	Paul Bisaro (Director) bought 7,500 shares at $3.69 ($28K), reported as a purchase (code P). Holdings up 8% to 97,441 shares. Not marked as a 10b5-1 plan trade.	SEC filing Filed May 14, 2026
Mar 9, 2026	Purchase (code P)	Samraat S. Raha (CEO and Director) bought 40,000 shares at about $5.00 ($200K), reported as a purchase (code P). Holdings up 9% to 493,104 shares. Not marked as a 10b5-1 plan trade.	SEC filing Filed Mar 9, 2026
Feb 25–27, 2026	Purchase (code P)	S. Louise Phanstiel (Director) bought 104,507 shares between Feb 25 and Feb 27 at about $4.73 ($495K), reported as a purchase (code P). Holdings up 59% to 281,951 shares. Not marked as a 10b5-1 plan trade.	SEC filing Filed Feb 27, 2026

38 routine transactions (such as grants, option exercises or tax withholding) are not listed.

$695K in purchases since Feb 27, 2026 · Purchases traded Feb 27, 2026 to Mar 9, 2026 · Closed

Insider	Value	Traded	Source
S. Louise Phanstiel (Director)	$495K	Feb 27, 2026	SEC filing
Samraat S. Raha (CEO)	$200K	Mar 9, 2026	SEC filing

No red flags in the last 12 months.

No key events in the last 12 months.

No 8-K filings in the last 12 months.

Red flags are objective triggers only: the item or form filed, never an opinion.

Follow MYGN in the Insider Ledger app

A plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.